Novo Nordisk (NVO) is set to report earnings for the second quarter on Wednesday morning after a first half in which the company's market of potential customers for its Ozempic and Wegovy weight-loss drugs expanded.

Analysts project that 澳洲幸运5官方开奖结果体彩网:Novo Nordisk's drugs will help lift the Danish drugmaker's revenue and income. Analyst estimates compiled by Visible Alpha project Novo Nordisk will report a year-over-year jump of about 26% in revenue to 68.47 billion Danish kroner ($9.9 billion), with a rise of nearly 10% in profit to 21.27 billion kroner ($3.08 billion).

Key Metric: Ozempic, Wegovy Sales

澳洲幸运5官方开奖结果体彩网:In the first quarter, Novo Nordisk said sales of Ozempic and Wegovy 🌺rose 25% year over year and said that demand would likely continue to outpaꦐce supply for the rest of 2024.

The weight-loss drug sales led Novo Nordisk to lift its guidance for the year, projecting🎶 revenue growth between 19% to 27%, slightly up from a previous projection of 18% to 26%.

Investors could expect that guidance to rise again when the company reports Wednesday. Novo Nordisk said in May that its updated figures included expectations that the drugs would face supply constraints over the course of 2024, and that revenue could grow further depending on the company's investments in production 澳洲幸运5官方开奖结果体彩网:capacity.

Busi🐬ness Spotlight: Weight-Loss Drug Productio🐬n, Market Expansion

Novo Nordisk and 澳洲幸运5官方开奖结果体彩网:Eli Lilly (LLY) have both said that the booming popularity of their weight-loss drugs has meant their supply will likely lag demand as they work to increase production. For its part, Novo Nordisk has 澳洲幸运5官方开奖结果体彩网:made acquisitions and investments to bolster its production capabilities for the drugs, including a $4.1 billion plan to expand its facilities in North Carolina by 2029.

Ozempic and Wegovy also have been introduced to new markets 澳洲幸运5官方开奖结果体彩网:like China over the first half of the year and studies over the last year have also led regulators to support updating the drugs' labels to include evidence that they can have 澳洲幸运5官方开奖结果体彩网:positive cardiovascular impacts along with their weight-loss benefits.

Wegovy also has received approval to start being sold in Australia, further expanding the drug's market, Reuters reported Thursday.

澳洲幸运5官方开奖结果体彩网:American depositary rec🥃eipts (ADRs) of Novo Nordisk finished Thurs𓂃day roughly flat and about 28% above where they started the year.